PI-3K/Akt and NF-κB/IκBα pathways are activated in Jurkat T cells in response to TRAIL treatment

Giorgio Zauli, Silvia Sancilio, Amelia Cataldi, Nadia Sabatini, Domenico Bosco, Roberta Di Pietro

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The aim of this work was to evaluate the involvement of survival pathways in the response of Jurkat T leukaemic cells sensitive to the cytotoxic action of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/Apo2L. Jurkat T cells express TRAIL-R2/ DR5 and TRAIL-R4/DcR2 receptors and start to die by apoptosis early (3 h) upon TRAIL administration reaching a dose-dependent increase in the percentage of dead cells within 48 h (up to 85-90%). This increase in cell death is accompanied by a dose-dependent significant (P <0.05) increase in the G0/G1 phase of the cell cycle and reverted by the treatment with a broad inhibitor of caspases, z-VAD-fmk. Co-treatment of the cells with inhibitors of PI-3 kinase (LY294002) and nuclear factor kappa B (NF-κB) (SN50) pathways leads to an earlier significantly increased cytotoxicity, respectively in the form of apoptosis and necrosis. Consistently with the data obtained with the pharmacological inhibitors, the activation and nuclear translocation of both PI-3K and NF-κB were observed. In summary, our results provide evidence that even in sensitive neoplastic cells TRAIL paradoxically activates pro-survival pathways, which protect against TRAIL-mediated death since their inhibition leads to an earlier and increased cytotoxicity.

Original languageEnglish
Pages (from-to)900-911
Number of pages12
JournalJournal of Cellular Physiology
Volume202
Issue number3
DOIs
Publication statusPublished - Mar 2005

Fingerprint

TNF-Related Apoptosis-Inducing Ligand
Jurkat Cells
T-cells
NF-kappa B
Phosphatidylinositol 3-Kinases
T-Lymphocytes
Cytotoxicity
Apoptosis
Cells
Cell Cycle Resting Phase
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Caspase Inhibitors
G1 Phase
Cell death
Cell Cycle
Cell Death
Necrosis
Tumor Necrosis Factor-alpha
Chemical activation
Pharmacology

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology

Cite this

Zauli, G., Sancilio, S., Cataldi, A., Sabatini, N., Bosco, D., & Di Pietro, R. (2005). PI-3K/Akt and NF-κB/IκBα pathways are activated in Jurkat T cells in response to TRAIL treatment. Journal of Cellular Physiology, 202(3), 900-911. https://doi.org/10.1002/jcp.20202

PI-3K/Akt and NF-κB/IκBα pathways are activated in Jurkat T cells in response to TRAIL treatment. / Zauli, Giorgio; Sancilio, Silvia; Cataldi, Amelia; Sabatini, Nadia; Bosco, Domenico; Di Pietro, Roberta.

In: Journal of Cellular Physiology, Vol. 202, No. 3, 03.2005, p. 900-911.

Research output: Contribution to journalArticle

Zauli, G, Sancilio, S, Cataldi, A, Sabatini, N, Bosco, D & Di Pietro, R 2005, 'PI-3K/Akt and NF-κB/IκBα pathways are activated in Jurkat T cells in response to TRAIL treatment', Journal of Cellular Physiology, vol. 202, no. 3, pp. 900-911. https://doi.org/10.1002/jcp.20202
Zauli, Giorgio ; Sancilio, Silvia ; Cataldi, Amelia ; Sabatini, Nadia ; Bosco, Domenico ; Di Pietro, Roberta. / PI-3K/Akt and NF-κB/IκBα pathways are activated in Jurkat T cells in response to TRAIL treatment. In: Journal of Cellular Physiology. 2005 ; Vol. 202, No. 3. pp. 900-911.
@article{168492435cc24473960d9ad4fa443ea5,
title = "PI-3K/Akt and NF-κB/IκBα pathways are activated in Jurkat T cells in response to TRAIL treatment",
abstract = "The aim of this work was to evaluate the involvement of survival pathways in the response of Jurkat T leukaemic cells sensitive to the cytotoxic action of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/Apo2L. Jurkat T cells express TRAIL-R2/ DR5 and TRAIL-R4/DcR2 receptors and start to die by apoptosis early (3 h) upon TRAIL administration reaching a dose-dependent increase in the percentage of dead cells within 48 h (up to 85-90{\%}). This increase in cell death is accompanied by a dose-dependent significant (P <0.05) increase in the G0/G1 phase of the cell cycle and reverted by the treatment with a broad inhibitor of caspases, z-VAD-fmk. Co-treatment of the cells with inhibitors of PI-3 kinase (LY294002) and nuclear factor kappa B (NF-κB) (SN50) pathways leads to an earlier significantly increased cytotoxicity, respectively in the form of apoptosis and necrosis. Consistently with the data obtained with the pharmacological inhibitors, the activation and nuclear translocation of both PI-3K and NF-κB were observed. In summary, our results provide evidence that even in sensitive neoplastic cells TRAIL paradoxically activates pro-survival pathways, which protect against TRAIL-mediated death since their inhibition leads to an earlier and increased cytotoxicity.",
author = "Giorgio Zauli and Silvia Sancilio and Amelia Cataldi and Nadia Sabatini and Domenico Bosco and {Di Pietro}, Roberta",
year = "2005",
month = "3",
doi = "10.1002/jcp.20202",
language = "English",
volume = "202",
pages = "900--911",
journal = "Journal of cellular and comparative physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - PI-3K/Akt and NF-κB/IκBα pathways are activated in Jurkat T cells in response to TRAIL treatment

AU - Zauli, Giorgio

AU - Sancilio, Silvia

AU - Cataldi, Amelia

AU - Sabatini, Nadia

AU - Bosco, Domenico

AU - Di Pietro, Roberta

PY - 2005/3

Y1 - 2005/3

N2 - The aim of this work was to evaluate the involvement of survival pathways in the response of Jurkat T leukaemic cells sensitive to the cytotoxic action of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/Apo2L. Jurkat T cells express TRAIL-R2/ DR5 and TRAIL-R4/DcR2 receptors and start to die by apoptosis early (3 h) upon TRAIL administration reaching a dose-dependent increase in the percentage of dead cells within 48 h (up to 85-90%). This increase in cell death is accompanied by a dose-dependent significant (P <0.05) increase in the G0/G1 phase of the cell cycle and reverted by the treatment with a broad inhibitor of caspases, z-VAD-fmk. Co-treatment of the cells with inhibitors of PI-3 kinase (LY294002) and nuclear factor kappa B (NF-κB) (SN50) pathways leads to an earlier significantly increased cytotoxicity, respectively in the form of apoptosis and necrosis. Consistently with the data obtained with the pharmacological inhibitors, the activation and nuclear translocation of both PI-3K and NF-κB were observed. In summary, our results provide evidence that even in sensitive neoplastic cells TRAIL paradoxically activates pro-survival pathways, which protect against TRAIL-mediated death since their inhibition leads to an earlier and increased cytotoxicity.

AB - The aim of this work was to evaluate the involvement of survival pathways in the response of Jurkat T leukaemic cells sensitive to the cytotoxic action of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/Apo2L. Jurkat T cells express TRAIL-R2/ DR5 and TRAIL-R4/DcR2 receptors and start to die by apoptosis early (3 h) upon TRAIL administration reaching a dose-dependent increase in the percentage of dead cells within 48 h (up to 85-90%). This increase in cell death is accompanied by a dose-dependent significant (P <0.05) increase in the G0/G1 phase of the cell cycle and reverted by the treatment with a broad inhibitor of caspases, z-VAD-fmk. Co-treatment of the cells with inhibitors of PI-3 kinase (LY294002) and nuclear factor kappa B (NF-κB) (SN50) pathways leads to an earlier significantly increased cytotoxicity, respectively in the form of apoptosis and necrosis. Consistently with the data obtained with the pharmacological inhibitors, the activation and nuclear translocation of both PI-3K and NF-κB were observed. In summary, our results provide evidence that even in sensitive neoplastic cells TRAIL paradoxically activates pro-survival pathways, which protect against TRAIL-mediated death since their inhibition leads to an earlier and increased cytotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=12944333065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12944333065&partnerID=8YFLogxK

U2 - 10.1002/jcp.20202

DO - 10.1002/jcp.20202

M3 - Article

C2 - 15389633

AN - SCOPUS:12944333065

VL - 202

SP - 900

EP - 911

JO - Journal of cellular and comparative physiology

JF - Journal of cellular and comparative physiology

SN - 0021-9541

IS - 3

ER -